Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Archives of Dermatology

• Publication date

  1993-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHDERM.1993.01680230073008PMID 8434976
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma.

  1992cited by this paper
• Interleukin-8 immunoreactivity in the skin of healthy subjects and patients with palmoplantar pustulosis and psoriasis.

  1992cited by this paper
• Human neutrophil activating peptide/interleukin 8 acts as an autoantigen in rheumatoid arthritis.

  1992cited by this paper
• Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 antibody in normal human serum.

  1992cited by this paper
• The Cause and Pathogenesis of the Eosinophilia-Myalgia Syndrome

  1992cited by this paper
• Neutrophil recruitment by intradermally injected neutrophil attractant/activation protein-1.

  1991cited by this paper
• Molecular pathology of collagen in cutaneous diseases.

  1991cited by this paper
• Structure and functional expression of a human interleukin-8 receptor.

  1991cited by this paper
• Anti‐Interleukin‐6 Antibodies in Normal Human Serum

  1991cited by this paper
• Cloning of complementary DNA encoding a functional human interleukin-8 receptor.

  1991cited by this paper
• Inflammatory properties of neutrophil-activating protein-1/interleukin 8 (NAP-1/IL-8) in human skin: a light- and electronmicroscopic study.

  1991cited by this paper
• Distribution and Characterization of Autoantibodies to Interleukin 1α in Normal Human Sera

  1990cited by this paper
• Interim guidance on the eosinophilia-myalgia syndrome.

  1990cited by this paper
• Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN‐alpha 2b and human IFN‐gamma in healthy blood donors

  1990cited by this paper
• Distribution and characterization of autoantibodies to interleukin 1 alpha in normal human sera.

  1990cited by this paper
• Autoantibodies to cytokines--friends or foes?

  1990cited by this paper
• Demonstration of neutralizing autoantibodies against IL-1 alpha in sera from patients with rheumatoid arthritis.

  1990cited by this paper
• Soluble interleukin‐2 receptor, interleukin‐2 and interleukin‐4 in sera and supernatants from patients with progressive systemic sclerosis

  1990cited by this paper
• Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils.

  1989cited by this paper
• Auto‐Antibodies to Tumour Necrosis Factor a in Healthy Humans and Patients with Inflammatory Diseases and Gram‐Negative Bacterial Infections

  1989cited by this paper
• The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes.

  1989cited by this paper
• Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration.

  1989cited by this paper
• Granulocyte chemotactic protein/interleukin-8 induces plasma leakage and neutrophil accumulation in rabbit skin.

  1989cited by this paper
• In vivo inflammatory activity of neutrophil-activating factor, a novel chemotactic peptide derived from human monocytes.

  1989cited by this paper
• IgG Autoantibodies against Interleukin 1α in Sera of Normal Individuals

  1989cited by this paper
• IgG autoantibodies against interleukin 1 alpha in sera of normal individuals.

  1989cited by this paper
• Structure determination of a human lymphocyte derived neutrophil activating peptide (LYNAP).

  1988cited by this paper
• Systemic scleroderma: clinical and pathophysiologic aspects

  1988cited by this paper
• A novel, NH2-terminal sequence-characterized human monokine possessing neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity

  1988cited by this paper
• Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

  1988cited by this paper
• Individuals infected with HIV possess antibodies against IL-2.

  1988cited by this paper
• Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes.

  1987cited by this paper
• Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines.

  1987cited by this paper
• Antibodies to alpha-interferon in a patient with systemic lupus erythematosus.

  1982cited by this paper

• Anti-Th/To Antibodies in Scleroderma: Good Prognosis or Serious Concern?

  2024cites this paper
• Role of Intravenous Immunoglobulin in Dermatologic Disorders

  2018cites this paper
• Inflammation and Immunity

  2017cites this paper
• Angiostatic and Angiogenic Chemokines in Systemic Sclerosis: An Overview

  2017cites this paper
• Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis.

  2016cites this paper
• The role of cytokine deficiencies and cytokine autoantibodies in clinical dermatology

  2016cites this paper
• The platelet serotonin‐release assay

  2015cites this paper
• Serum Amyloid A Is a Marker for Pulmonary Involvement in Systemic Sclerosis

  2015cites this paper
• Systemic Sclerosis, Scleroderma

  2014cites this paper
• Updates on Morphea: Role of Vascular Injury and Advances in Treatment

  2013cites this paper
• Chemokines and Their Receptors Are Key Players in the Orchestra That Regulates Wound Healing

  2013cites this paper
• Autoimmunity Diseases of the Skin

  2013cites this paper
• Systemic Sclerosis Anti-Endothelial Cell Antibodies in

  2013cites this paper
• The role of Microsomal prostaglandin synthase-1 (mPGES-1) and Ephrin B2 in Scleroderma

  2013cites this paper
• Systemic Sclerosis 2011

  2012cites this paper
• Scleroderma

  2012cites this paper
• The Many Faces of Interleukin-6: The Role of IL-6 in Inflammation, Vasculopathy, and Fibrosis in Systemic Sclerosis

  2011cites this paper
• Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis

  2011influential citation
• Cytokine profiles in localized scleroderma and relationship to clinical features.

  2011cites this paper
• Pathogenesis of systemic sclerosis

  2011cites this paper
• 11 – Disorders of collagen

  2010cites this paper
• Defining the neutrophil phenotype in systemic sclerosis

  2010cites this paper
• Expression and regulation of monocyte chemoattractant protein-3 (MCP-3) in fibrosis

  2009cites this paper
• Fibrosis in systemic sclerosis.

  2008cites this paper
• Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4.

  2008cites this paper
• Role of Heparin-Dependent Antigens in Immune Heparin-Induced Thrombocytopenia

  2007cites this paper
• Intravenous Immunoglobulin and Cytokines

  2007cites this paper
• Pathogenese der systemischen Sklerose (Sklerodermie)

  2006cites this paper
• Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.

  2006cites this paper
• Chemokines and Chemokine Receptors in Scleroderma

  2006cites this paper
• Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.

  2004cites this paper
• Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being.

  2003cites this paper
• Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis.

  2003cites this paper
• Non organ based laboratory markers in systemic sclerosis.

  2003cites this paper
• [Case of eosinophilic fasciitis with change of serum Th 1/Th 2 cytokine level which correlated with disease activity].

  2002cites this paper
• Chemokines and chemokine receptors in the pathogenesis of systemic sclerosis

  2002cites this paper
• Immunomodulatory action of intravenous immunoglobulin

  2002cites this paper
• Drug-induced and drug-dependent immune thrombocytopenias.

  2001cites this paper
• Eosinophilic fasciitis (Shulman's syndrome): case reports and review of the literature.

  2001cites this paper
• Assessment of damage and activity in systemic sclerosis

  2000cites this paper
• Detection of autoantibodies to cytokines

  2000cites this paper
• In vivo modulation of cytokine synthesis by intravenous immunoglobulin

  1999cites this paper
• Die eosinophile Fasziitis (Shulman-Syndrom)

  1999cites this paper
• Anti-Endothelial Cell Antibodies in Systemic Sclerosis

  1999cites this paper
• Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers

  1998cites this paper
• This information is current as Human Mast Cells IL-8 Receptor Type CXCR 1 and CXCR 2 on Expression and Functional Activity of the

  1998cites this paper
• Peritoneal fluid concentrations of interleukin-8 in women with endometriosis: relationship to stage of disease.

  1998cites this paper
• Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells.

  1998cites this paper
• Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts.

  1998cites this paper
• Spontaneous cytokine gene expression by cultured skin fibroblasts of systemic sclerosis. Correlation with collagen synthesis.

  1998cites this paper
• The biological basis of immune heparin-induced thrombocytopenia.

  1998cites this paper
• Systemic treatment of severe psoriasis

  1997cites this paper
• Serum cytokine and anti-Fc gamma R autoantibody measurements in patients with systemic sclerosis.

  1996cites this paper
• IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines.

  1996cites this paper
• Pathophysiology of the eosinophilia-myalgia syndrome.

  1996cites this paper
• Immunopathogenesis of systemic sclerosis.

  1996cites this paper
• Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia.

  1996cites this paper
• Pathogenesis of L-tryptophan eosinophilia myalgia syndrome.

  1996cites this paper
• Detection of anti-Fc gamma R antibodies and different cytokines in sera from patients with systemic sclerosis.

  1996cites this paper
• Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.

  1995cites this paper
• Cytokine autoantibodies in rheumatoid arthritis.

  1995cites this paper
• Chemokines and tissue injury.

  1995cites this paper
• Correlation of Serum Interleukin-8 and Cell Surface Lysosome-associated Membrane Protein with Clinical Disease Activity in Systemic Lupus Erythematosus

  1994cites this paper
• The evolving spectrum of eosinophilia myalgia syndrome.

  1994cites this paper
• Correlation of serum interleukin-8 and cell surface lysosome-associated membrane protein expression with clinical disease activity in systemic lupus erythematosus.

  1994cites this paper
• Demonstration of interleukin 8 in serum samples of patients with localized scleroderma.

  1994cites this paper
• Cytokine production and aging: overproduction of IL-8 in elderly males in response to lipopolysaccharide.

  1994cites this paper
• Anti‐Cytokine Nature of Natural Human Immunoglobulin: One Possible Mechanism of the Clinical Effect of Intravenous Immunoglobulin Therapy

  1994cites this paper
• Toxic oil syndrome and eosinophilia-myalgia syndrome: May 8-10, 1991, World Health Organization meeting report.

  1993cites this paper
• Extended Report

  year unknowncites this paper